Status:
UNKNOWN
Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Mucocutaneous Lymph Node Syndrome
Eligibility:
All Genders
Up to 17 years
Phase:
PHASE1
Brief Summary
In this study, the investigator plan to prescribe Methylprednisolone pulse therapy in Kawasaki disease patients with coronary artery lesions or aneurysm formation beyond acute stage to investigate the...
Detailed Description
Kawasaki disease is the most common systemic vasculitis in children. Coronary artery aneurysms may develop in 20-25% of untreated patients. Intravenous immune globulin (IVIG) can reduce coronary-arter...
Eligibility Criteria
Inclusion
- Kawasaki disease patients with coronary artery dilation or aneurysm formation after acute stage (at lease 3 weeks after IVIG treatment)
Exclusion
- patients meet the contraindications of Methylprednisolone sodium succinate, e.g., allergic to Methylprednisolone sodium succinate, premature infant, immune system related thrombocytopathy, immunodeficiency, any congenital diseases.
Key Trial Info
Start Date :
April 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04509219
Start Date
April 15 2020
End Date
August 31 2023
Last Update
August 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 83301